N/A N=45 Individualizing Surveillance Mammography for Older Breast Cancer Survivors
Breast Cancer
Primary: Rate of Change in Intentions for Mammography in the Next Year — 39; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Performance of Toric Silicone Hydrogel Contact Lenses
Astigmatism · Myopia
Primary: Lens Handling (Insertion and Removal) — 9.47; 8.33 units on a scale
Phase 2 N=66 An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0 — 0.13; 0.48; 0.22; 0.91 Probability of decline — p=<0.0001
Phase 2 N=88 Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
Psoriasis
Primary: Percentage of Participants With Success Rate 1 (SR1) at Week 8 — 4.5; 0.0 percentage of participants
Phase 3 N=119 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events — 41; 70; 14; 26 Participants
Phase 1 N=21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Mesothelioma
Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg
N/A N=102 Cardiac Resynchronization in the Elderly
Heart Failure
Primary: Enrollment — 22; 20; 18; 42 Participants
N/A N=44 DDBT Adapted Problem Solving Treatment for Primary Care
Depression · PTSD
Primary: Patient Health Questionnaire-9 (PHQ-9) — 13.3; 10.7 score on a scale
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants
N/A N=324 Connect-Home Clinical Trial
Transitional Care · Caregivers · Patient Discharge
Primary: Care Transitions Measure-15 Score 7 Days After Skilled Nursing Facility Discharge — 75.80; 68.33 score on a scale — p=.62
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Phase 2 N=1,301 Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants
Early Phase 1 N=90 The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression
Alzheimer's Disease · Dementia
Primary: Medication Appropriateness Index — 11.2; 9.4 units on a scale
Phase 4 N=45 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
Relapsed and/or Refractory Multiple Myeloma
Primary: Progression-Free Survival (PFS) Rate at 12 Months From the Start of Study Treatment — 50.0; 48.7; 48.9 Percentage of Participants
Phase 3 N=507 Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Painful Diabetic Neuropathy · Diabetic Neuropathy, Painful
Primary: Change in the Average 24 Hour Pain Score From Baseline to Day 90 — -1.80; -1.57 units on a scale